Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC. Get the latest research information from NIH.

Your Environment. Your Health.

Biomolecular Screening Branch

The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

Warren Casey, Ph.D., D.A.B.T.
Warren Casey, Ph.D.
Acting Chief, Biomolecular Screening Branch
Tel 984-287-3118
warren.casey@nih.gov
P.O. Box 12233
Mail Drop K2-16
Durham, N.C. 27709

Research Summary

Biomolecular Screening Branch Genetic Toxicology Group Molecular Toxicology & Genomics Group Toxicoinformatics Group Toxicology in the 21st Century

The Biomolecular Screening Branch (BSB), headed by Warren Casey, Ph.D., develops and carries out programs in medium and high throughput screening of environmental substances for rapid detection of biological activities of significance to toxicology.

The Branch develops analysis tools and approaches that integrate its assessment with findings from traditional toxicology.

The Branch also administers the National Toxicology Program (NTP) High Throughput Screening (HTS) Initiative called Tox21, a major initiative within NTP's Roadmap to achieve its vision for Toxicology in the 21st Century. Tox21 places an increased emphasis on the use of alternative assays for targeting the key pathways, molecular events, or processes linked to disease or injury, and attempts to incorporate them into a research and testing framework. In support of this Program, the Biomolecular Screening Branch represents the NTP in the Toxicology in the 21st Century Partnership.

Tox21 is a unique collaboration between several federal agencies to research and test chemicals in a new way. The goals of the Tox21 partnership are to:

  • Identify patterns of compound-induced biological response in order to characterize toxicity/disease pathways, facilitate cross-species extrapolation, and model low-dose extrapolation
  • Prioritize compounds for more extensive toxicological evaluation
  • Develop predictive models for biological response in humans

The Branch’s involvement in Tox21 complements the support the Biomedical Screening Branch provides NTP in programmatic needs to evaluate the adverse effects of chemical exposure on human health. Branch scientists strive to improve the relevance of assay findings to human health outcomes, providing data from a variety of high throughput and/or high content approaches and developing computational approaches to best analyze those data.

The goals of the Biomolecular Screening Branch are carried out by 3 groups and adjunct staff from the Division of the National Toxicology Program and the Division of Intramural Research:

Selected Publications

Back
to Top